A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective

Autor(es):Mostrar menos -

Vuitika, Larissa ; Cortes, Nelson ; Malaquias, Vanessa B. ; Silva, Jaqueline D. Q. ; Lira, Aline ; Prates-Syed, Wasim A. ; Schimke, Lena F. ; Luz, Daniela ; Duraes-Carvalho, Ricardo ; Balan, Andrea ; Camara, Niels O. S. ; Cabral-Marques, Otavio ; Krieger, Jose E. ; Hirata, Mario H. ; Cabral-Miranda, Gustavo

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 14, n. 1, p. 17-pg., 2024-10-16.

Resumo

Vaccination has played a critical role in mitigating COVID-19. Despite the availability of licensed vaccines, there remains a pressing need for improved vaccine platforms that provide high protection, safety, and versatility, while also reducing vaccine costs. In response to these challenges, our aim is to create a self-adjuvanted vaccine against SARS-CoV-2, utilizing Virus-Like Particles (VLPs) as the foundation. To achieve this, we produced bacteriophage (Q beta) VLPs in a prokaryotic system and purified them using a rapid and cost-effective strategy involving organic solvents. This method aims to solubilize lipids and components of the cell membrane to eliminate endotoxins present in bacterial samples. For vaccine formulation, Receptor Binding Domain (RBD) antigens were conjugated using chemical crosslinkers, a process compatible with Good Manufacturing Practice (GMP) standards. Transmission Electron Microscopy (TEM) confirmed the expected folding and spatial configuration of the Q beta VLPs vaccine. Additionally, vaccine formulation assessment involved SDS-PAGE stained with Coomassie Brilliant Blue, Western blotting, and stereomicroscopic experiments. In vitro and in vivo evaluations of the vaccine formulation were conducted to assess its capacity to induce a protective immune response without causing side effects. Vaccine doses of 20 mu g and 50 mu g stimulated the production of neutralizing antibodies. In in vivo testing, the group of animals vaccinated with 50 mu g of vaccine formulation provided complete protection against virus infection, maintaining stable body weight without showing signs of disease. In conclusion, the Q beta VLPs-RBD vaccine has proven to be effective and safe, eliminating the necessity for supplementary adjuvants and offering a financially feasible approach. Moreover, this vaccine platform demonstrates flexibility in targeting Variants of Concern (VOCs) via established conjugation protocols with VLPs. (AU)

• Processo FAPESP: 19/14526-0 - Desenvolvimento de vacinas contra Streptococcus pyogenes e Chikungunya utilizando VLPs
• Beneficiário: Gustavo Cabral de Miranda
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 21/08468-8 - Desenvolvimento de vacinas baseadas em VLPs contra SARS-CoV-2 e outros Coronavírus humanos
• Beneficiário: Wasim Aluísio Prates Syed
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 20/04667-3 - Desenvolvimento de vacinas contra Streptococcus pyogenes e Chikungunya utilizando VLPs
• Beneficiário: Gustavo Cabral de Miranda
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores
• Processo FAPESP: 21/03102-5 - Desenvolvimento de vacinas seguras e eficazes contra o Vírus Chikungunya baseada em VLPs homólogo e heterólogo
• Beneficiário: Aline Aparecida de Lima Lira
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 20/09404-0 - Desenvolvimento de vacina anti-SARS-CoV-2 utilizando VLPs
• Beneficiário: Larissa Vuitika
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 21/03508-1 - Desenvolvimento de uma vacina eficaz e segura anti-Zika Vírus utilizando VLPs quimérica expressando a proteína do Envelope Domínio III (E-DIII)
• Beneficiário: Nelson Côrtes de Oliveira
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto